Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Trial of Leflunomide for the Treatment of Severe COVID-19 in Patients With a Concurrent Malignancy

NCT04532372 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT04532372
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04532372 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Trial of Leflunomide for the Treatment of Severe COVID-19 in Patients With a Concurrent Malignancy
Lead sponsor
City of Hope Medical Center
Phase
Phase 1/2
Overall status
Completed
Start date
January 7, 2021
Completion date
October 27, 2021
Enrollment
2 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hematopoietic and lymphoid cell neoplasm, malignant solid neoplasm, symptomatic covid-19 infection laboratory-confirmed